John Pinching is an editor for PharmaTimes Media Ltd, specializing in the pharmaceutical industry. With a focus on providing up-to-date news and insights, John covers a wide range of topics including drug approvals, mergers and acquisitions, partnerships, and regulatory developments within the pharmaceutical sector.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
United Kingdom (National)
Not enough data
John's coverage heavily focuses on healthcare and pharmaceutical industry, particularly press releases and data citations. He may prefer pitches with access to exclusive data or insights into the latest advancements in pharmaceuticals, medical treatments, clinical trials, mergers and acquisitions within the healthcare sector.
Given his extensive use of press releases as sources for his articles, he may be interested in receiving well-documented pitches with detailed information about newsworthy developments within the healthcare and pharmaceutical industries.
While John does not have a specific geographic focus mentioned, it is evident that his interest lies in global developments within the healthcare and pharmaceutical sectors. Therefore, he would likely appreciate relevant information from experts across different regions impacting these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: John Pinching
Phase 1 and 2 studies show promising results for anito-cel therapy
By: John Pinching
New initiatives to tackle AI-related challenges in life sciences
By: John Pinching
First car t-cell therapy accepted for second-line treatment in Scotland
By: John Pinching
New treatment option approved for women in Scotland
By: John Pinching
Insight into double-blind, phase i/ii clinical trial for oesophageal cancer
By: John Pinching
Eco-friendly inhalers aim to reduce environmental impact
By: John Pinching
New long-term partnership to address neurological disorder treatments
By: John Pinching
First patient dosed in phase 1b trial of MB310 therapy
By: John Pinching
First participant vaccinated in study of ovx836 booster dose
By: John Pinching
Therapy shows high efficacy in initial trial phase
(833) 317-6278 
